TY - JOUR
T1 - Prospective study on embolization of intracranial aneurysms with the pipeline device (PREMIER study)
T2 - 3-year results with the application of a flow diverter specific occlusion classification
AU - Hanel, Ricardo A.
AU - Cortez, Gustavo M.
AU - Lopes, Demetrius Klee
AU - Nelson, Peter Kim
AU - Siddiqui, Adnan H.
AU - Jabbour, Pascal
AU - Mendes Pereira, Vitor
AU - István, Istvan Szikora
AU - Zaidat, Osama O.
AU - Bettegowda, Chetan
AU - Colby, Geoffrey P.
AU - Mokin, Maxim
AU - Schirmer, Clemens M.
AU - Hellinger, Frank R.
AU - Given, Curtis
AU - Krings, Timo
AU - Taussky, Philipp
AU - Toth, Gabor
AU - Fraser, Justin F.
AU - Chen, Michael
AU - Priest, Ryan
AU - Kan, Peter
AU - Fiorella, David
AU - Frei, Donald
AU - Aagaard-Kienitz, Beverly
AU - Diaz, Orlando
AU - Malek, Adel M.
AU - Cawley, C. Michael
AU - Puri, Ajit S.
AU - Kallmes, David F.
N1 - Funding Information:
The PREMIER study was supported by by Medtronic, Inc.
Funding Information:
RAH is a consultant for Medtronic, Stryker, Cerenovous, Microvention, Balt, Phenox, Rapid Medical, and Q’Apel; he is on advisory board for MiVI, eLum, Three Rivers, Shape Medical and Corindus; he has received unrestricted research grants from NIH, Interline Endowment, Microvention, Stryker, CNX; he is an investor/stockholder for InNeuroCo, Cerebrotech, eLum, Endostream, Three Rivers Medical Inc, Scientia, RisT, BlinkTBI, and Corindus. DKL is a consultant for Asahi, Medtronic, and Stryker; has received honoraria from Siemens, Medtronic, Stryker, and Phenox. PKN is a consultant for Medtronic, Phenox, and GmbH. AHS is a modest consultant for Amnis Therapeutics, Boston Scientific, Canon Medical Systems USA, Cerebrotech Medical Systems, Claret Medical, Corindus, Endostream Medical, Guidepoint Global Consulting, Imperative Care, Integra, Rapid Medical, Rebound Therapeutics Corp, Silk Road Medical, StimMed, Stryker, Three Rivers Medical, VasSol, and WL Gore and Associates; he is a consultant and serves on the national PI/steering committee for Cerenovus, Medtronic, MicroVention, and Penumbra; he serves on the National PI/steering committee for the POSITIVE Trial for the Medical University of South Carolina and as DSMB Chair for the HEAT Trial for Northwest University and has ownership interest in Amnis Therapeutics, Apama Medical, BlinkTBI, Buffalo Technology Partners, Cardinal Health, Cerebrotech Medical Systems, Claret Medical, Cognition Medical, Endostream Medical Ltd, Imperative Care, International Medical Distribution Partners, Rebound Therapeutics Corp, Silk Road Medical, StimMed, Synchron, Three Rivers Medical, and Viseon. PJ serves as a consultant for Medtronic, Cerenovus, and Microvention. VMP serves as a consultant/steering committee member for Stryker, Penumbra, and Balt, and as a consultant for Medtronic and Neurovasc, and receives a research grant from Philips. ISI serves as a scientific consultant regarding trial design and conduct to Medtronic. OOZ is a consultant for Medtronic, Stryker, Penumbra, and Cerenovus. CB is a consultant for Depuy-Synthes, Bionaut labs, and Galectin Therapeutics. GPC serves as a consultant for Medtronic, Microvention-Terumo, and Stryker. MM serves as a consultant for Cerebrotech, Imperative Care, and Penumbra; receives consulting fees from Medtronic, Cerenovus, and Canon Medical; and is a member of the Journal of NeuroInterventional Surgery editorial board. CMS has received honoraria from the American Association of Neurological Surgeons and Toshiba, and has ownership interest in NTI. CG serves as a consultant, proctor, and on the Speakers’ Bureau for Medtronic and Stryker. TK is a consultant for Stryker, Cerenovus, Penumbra, and Medtronic. PT serves as a consultant for Stryker Neurovascular, Cerenovus, and Medtronic. GT serves as a consultant for Dynamed EBSCO and Microvention; and is a member of the Journal of NeuroInterventional Surgery editorial board. JFF is an equity interest holder for Fawkes Biotechnology, LLC, and Cerelux; is a consultant for Stream Biomedical, Penumbra, and Medtronic; and is a member of the Journal of NeuroInterventional Surgery editorial board. MC is a consultant for Medtronic, Stryker, Penumbra, Genentech, and GE; and a member of the Journal of NeuroInterventional Surgery editorial board. RP is a consultant for Medtronic, Stryker, and Cerenovus. PK is a consultant for Stryker Neurovascular, Medtronic, and Cerenovus; and a member of the Journal of NeuroInterventional Surgery editorial board. DFi is a consultant for Arsenal Medical, Balt USA, Cerenovous, Marblehead, Medtronic, MENTICE-Vascular Simulations, Microvention, Neurogami, Qapel Medical, RAPID Medical, RAPID.AI, Stryker, and Siemens; received research support from Balt USA, Microvention, Penumbra, Siemens, and Stryker; has received honorarium from Qapel Medicine; is a stockholder in Marblehead, MENTICE-Vascular Simulations, and Neurogami; and a member of the Journal of NeuroInterventional Surgery editorial board. DFr is a consultant and on the Speakers’ Bureau for Penumbra, Stryker Neurovascular, Genentech, MicroVention, and Codman. OD serves as a proctor for Microvention/Terumo. AMM is a cofounder, investor, and shareholder of CereVasc. ASP consults for and has received research grants from Medtronic Neurovascular, Stryker Neurovascular, and Cerenovus; serves as a consultant for Microvention, Agile, Merit, Corindus, QApel, Arsenal, and Imperative Care. DFK is president of Marblehead Medical and has patent pending in balloon catheter technologies; he has received research support from Medtronic, MicroVention, NeuroSave, Neurogami, Sequent Medical, NeuroSigma, and Insera; and serves on the Scientific Advisory Board for Triticum and Boston Scientific.
Publisher Copyright:
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2022
Y1 - 2022
N2 - Background: The pipeline embolization device (PED; Medtronic) has presented as a safe and efficacious treatment for small-and medium-sized intracranial aneurysms. Independently adjudicated long-Term results of the device in treating these lesions are still indeterminate. We present 3-year results, with additional application of a flow diverter specific occlusion scale. Methods: PREMIER (prospective study on embolization of intracranial aneurysms with pipeline embolization device) is a prospective, single-Arm trial. Inclusion criteria were patients with unruptured wide-necked intracranial aneurysms ≤12 mm. Primary effectiveness (complete aneurysm occlusion) and safety (major neurologic event) endpoints were independently monitored and adjudicated. Results: As per the protocol, of 141 patients treated with a PED, 25 (17.7%) required angiographic follow-up after the first year due to incomplete aneurysm occlusion. According to the Core Radiology Laboratory review, three (12%) of these patients progressed to complete occlusion, with an overall rate of complete aneurysm occlusion at 3 years of 83.3% (115/138). Further angiographic evaluation using the modified Cekirge-Saatci classification demonstrated that complete occlusion, neck residual, or aneurysm size reduction occurred in 97.1%. The overall combined safety endpoint at 3 years was 2.8% (4/141), with only one non-debilitating major event occurring after the first year. There was one case of aneurysm recurrence but no cases of delayed rupture in this series. Conclusions: The PED device presents as a safe and effective modality in treating small-and medium-sized intracranial aneurysms. The application of a flow diverter specific occlusion classification attested the long-Term durability with higher rate of successful aneurysm occlusion and no documented aneurysm rupture. Trial registration: NCT02186561.
AB - Background: The pipeline embolization device (PED; Medtronic) has presented as a safe and efficacious treatment for small-and medium-sized intracranial aneurysms. Independently adjudicated long-Term results of the device in treating these lesions are still indeterminate. We present 3-year results, with additional application of a flow diverter specific occlusion scale. Methods: PREMIER (prospective study on embolization of intracranial aneurysms with pipeline embolization device) is a prospective, single-Arm trial. Inclusion criteria were patients with unruptured wide-necked intracranial aneurysms ≤12 mm. Primary effectiveness (complete aneurysm occlusion) and safety (major neurologic event) endpoints were independently monitored and adjudicated. Results: As per the protocol, of 141 patients treated with a PED, 25 (17.7%) required angiographic follow-up after the first year due to incomplete aneurysm occlusion. According to the Core Radiology Laboratory review, three (12%) of these patients progressed to complete occlusion, with an overall rate of complete aneurysm occlusion at 3 years of 83.3% (115/138). Further angiographic evaluation using the modified Cekirge-Saatci classification demonstrated that complete occlusion, neck residual, or aneurysm size reduction occurred in 97.1%. The overall combined safety endpoint at 3 years was 2.8% (4/141), with only one non-debilitating major event occurring after the first year. There was one case of aneurysm recurrence but no cases of delayed rupture in this series. Conclusions: The PED device presents as a safe and effective modality in treating small-and medium-sized intracranial aneurysms. The application of a flow diverter specific occlusion classification attested the long-Term durability with higher rate of successful aneurysm occlusion and no documented aneurysm rupture. Trial registration: NCT02186561.
KW - aneurysm
KW - flow diverter
KW - intervention
UR - http://www.scopus.com/inward/record.url?scp=85142770392&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142770392&partnerID=8YFLogxK
U2 - 10.1136/neurintsurg-2021-018501
DO - 10.1136/neurintsurg-2021-018501
M3 - Article
C2 - 35292570
AN - SCOPUS:85142770392
JO - Journal of neurointerventional surgery
JF - Journal of neurointerventional surgery
SN - 1759-8478
M1 - 018501
ER -